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Gene therapy represents a promising novel treatment strategy for colorectal cancer. Preclinical data has been encouraging and
several clinical trials are underway. Many phase 1 trials have proven the safety of the reagents but have yet to demonstrate signiﬁcant
therapeutic beneﬁt. Ongoing eﬀorts are being made to improve the eﬃciency of gene delivery and accuracy of gene targeting with
theaimofenhancingantitumorpotency.Itisenvisagedthatgenetherapywillbeusedincombinationwithothertherapiesincluding
surgery, chemotherapy, and radiotherapy to facilitate the improvements in cancer treatments in the future.
INTRODUCTION
Currently, 600 gene therapy clinical trial protocols
have been activated in the U.S., 60% of which pertain
to cancer gene therapy. Nearly 3500 patients have been
treated within these protocols, of which approximately
2400 were patients with cancer [1]. Similarly in the U.K.,
of approximately 70 gene therapy protocols approved or
under review by GTAC, 70% relates to cancer gene ther-
apy [2].
This increase in clinical trial activity is underpinned
by the expansion of the number of therapeutic vectors in
preclinicaldevelopmentandscientiﬁcinnovationwithre-
spect to novel mechanistic approaches to tumour-cell kill.
This article aims to provide an overview of the current
clinical state of gene therapy, especially focusing on the
trials, for colorectal cancer.
IMMUNE STIMULATION
The aim of immune stimulation is to activate a
tumour-speciﬁc immune response, which may be either
cell-mediated or antibody dependent, against the tumour
cells. Several approaches to stimulate the key mediators of
immune function have been tested in preclinical experi-
ments and have now entered clinical trials, including the
following approaches.
Utilizationofhumanleukocyteantigen(HLA)to
stimulateT-cellresponse
HLA class-I molecules are down regulated in up to
60% of colorectal cancers. Animal studies have demon-
strated that the expression of foreign MHC (the analogue
of HLA in humans) on tumours can induce a T cell-
dependent antitumour immune response, not only to the
foreignMHCbutalsotopreviouslyunrecognisedtumour
associated antigens [3].
On the basis of preclinical models, gene transfer of
the HLA class-I molecule, HLA-B7, has been examined
in clinical trials. In one trial, an allogeneic HLA-B7 plas-
mid in a lipid vector was administered via direct in-
tratumoural injection to HLA-B7-negative patients with
melanoma. Gene transfer rate was 93% when measured
by polymerase chain reaction (PCR) and HLA-B7 protein
was found in 50% of biopsied tumours by immunohis-
tochemistry (IHC). Eight of 15 evaluated patients devel-
oped anti-HLA-B7 CD8+ cytotoxic T cells (CTLs), and
7 patients had tumour reduction (4 partial responses)
[4]. A phase II trial reported a response rate in evalu-
able patients approaching 15%, including two complete
responses,demonstratingthistobeasafeandactivetreat-
ment against melanoma [5].
This trial has been extended to include patients with
hepatic colorectal metastases, in which the vector was in-
jected intratumourally under ultrasound guidance. Of 15
patients evaluated, 14 had detectable transgenic DNA by
PCR, and HLA-B7 protein was detected by immunohis-
tochemistry (IHC) in 63% of biopsied lesions. A biologi-
cal response was evident as induction of B7-speciﬁc CTLs
in peripheral blood of 8 patients and also inﬁltration of
CD8+ TcellsintosometumoursonIHC.However,noob-
jective responses were seen [6]. This creates an interesting
tensionastowhetherinductionofaCTLresponseissuﬃ-
cient to encourage further development of this immuno-
genetic approach, in the absence of bona ﬁde reduction
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this sort of treatment would be as an adjuvant following
resection of the primary tumour leaving a minimal resid-
ual volume. Although logical, clinical trials of this sort re-
quirethousandsofpatients,anenormouscommitmentof
resource on the basis of an immune assay which may not
correlate with eﬃcacy.
UtilizationofcytokinestostimulateTcellresponse
Cytokines play a key role in coordinating the immune
response. Therefore, the insertion of genes encoding cy-
tokines presents a potential strategy to increase the im-
munogenicity of tumours and overcome immune toler-
ance. Preclinical models have tested a range of cytokines
including interleukins 2, 4, and 12 (IL-2, -4, -12), granu-
locyte macrophage colony-stimulating factor (GM-CSF),
and interferon gamma (IFN-γ). In general, in vivo mod-
els conﬁrm that tumour-speciﬁc immunity can be gener-
atedbycytokine-transducedtumourcells.However,while
this is often strong enough to prevent tumour forma-
tion/growth when rechallenged with new untransduced
tumour cells, it is less eﬃcient in eradicating established
tumours.
Interleukin2asaneffector
Autologous ﬁbroblasts from 10 colorectal-cancer pa-
tients (used for their ease of growth in tissue culture
and transducibility by retrovirus vectors expressing cy-
tokines) were transduced with a retrovirus carrying the
IL-2 gene and mixed with autologous irradiated tumour
cells prior to subcutaneous reinjection [7]. In two of six
evaluable patients, there was a successful induction of
tumour-speciﬁc CTL precursors, however, no objective
responsesweredemonstrated.Anotherapproachhasbeen
to transfect autologous immune eﬀector cells with the
IL-2 gene. Preclinical studies have shown that cytokine-
induced killer cells (CIKs non-MHC restricted cytotoxic
lymphocytes) can eradicate tumours in nude mice. In a
phase I study, 10 patients with a range of diﬀerent malig-
nancies were treated with autologous CIKs derived from
peripheral blood mononuclear cells, PBMCs, transfected
ex vivo by electroporation with an IL-2 plasmid before
reinfusion intravenously. There was an increase in serum
IFN-γ,GM-CSF ,andT GF -β duringtreatmentandalsoan
increase in the cytotoxic activity of circulating lympho-
cytes tested against a range of HLA-matched carcinoma
cell lines. One patient with follicular B cell lymphoma
achieved a complete response [8] and the associated side
eﬀect proﬁle comprised mainly of fever and myalgia.
Two further phase I studies treating patients with a
range of advanced cancers have utilized either allogeneic
ﬁbroblasts secreting IL-2, or an IL-2 DNA/lipid complex
(leuvectin) delivered by direct intratumoural injection.
Both approaches were well tolerated with evidence of bi-
ological activity (detection of IL-2 on tumour biopsy and
tumour inﬁltration by T cells) in vivo as well as clinical
objective responses in some patients (with melanoma or
renal carcinoma).
In summary, cytokine gene therapy appears to be safe
w h e nm e d i a t e dv i aan u m b e ro fd i ﬀerent vectors but de-
spite evidence of biological activity objective responses
have been rare.
Vaccinationagainsttumour-speciﬁcantigens
Tumour-associated antigens have been identiﬁed for
a range of human tumours including viral antigens (eg,
HPV E6, E7), mutated oncogenes (eg, ras), and nonmu-
tated onco-fetal proteins (eg, CEA). Since T cell epitopes
to these antigens have been identiﬁed, they may serve as
targets for CTLs under appropriate conditions. Molecular
characterization of tumour-associated antigens and iden-
tiﬁcation of their genes has allowed the development of
recombinant vaccines in which a vector is used to intro-
duce DNA encoding tumour-associated antigens into pa-
tients.Viruses(especially,poxviruses)presentantigenand
inducebothhumoralandcell-mediatedresponses.There-
fore, copresentation of tumour-associated protein with
the vaccinia vector may enhance immunogenicity and in-
crease the possibility of tumour rejection.
Carcinoembryonic antigen (CEA) is a cell surface gly-
coprotein over expressed on the majority of colorectal
cancer cells, and is expressed at low levels in normal colon
and biliary epithelium. On the basis of diﬀerential expres-
sion levels, CEA has been selected as a potential target
for immunotherapy approaches. Diﬀerent methods have
been utilized in clinical trials.
Vacciniavector
Several phase I trials have now tested recombinant
vaccinia vectors encoding full length CEA administered
subcutaneously or intradermally at doses between 107–
108 pfu to patients with metastatic colorectal cancer [9].
Side eﬀects include low-grade fever, fatigue, and inﬂam-
mation at the injection site. The vaccine was able to in-
duce a CTL response to CEA epitopes but no objective
tumour responses.
Apotentialproblemwithvacciniavectorsisthegener-
ation of neutralizing antibodies, which may limit eﬃcacy.
Canarypox viruses, are not pathogenic in humans, do not
replicate in human cells and may therefore be given re-
peatedly without neutralization by antibodies. A recom-
binant canarypox virus containing the human CEA gene
has demonstrated antitumour eﬃcacy in mice. In a phase
I trial of this vector (Avipox), patients with advanced CEA
positive tumours were treated with three monthly intra-
muscular injections. In seven of nine evaluated patients,
CEA-speciﬁc CTL responses were induced without objec-
tive tumour shrinkage [10]. A novel approach to generate
an immune response to CEA is the development of anti-
CEA “designer T cells.” In a phase I trial, T cells from pa-
tients were transduced by retrovirus delivery of chimaeric
Ig-T-Cell receptor genes to generate immune eﬀector cells
which bind speciﬁcally to CEA positive cells before rein-
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1011 T cells although no objective reductions in tumour
volume were documented.
Most tumours do not express costimulatory mole-
cules and therefore, expression of such molecules on tu-
mours may enable presentation of tumour antigens di-
rectly to T cells, reducing the need for professional anti-
gen presenting cells (APCs). Further, systemic immunity
against unmodiﬁed tumour cells (distant bystander ef-
fect) may be evoked. Since T cell activation requires both
as pe c i ﬁ ca n t i g e ne p i t o pea n dac o s t i m u l a t o rys i gn a l ,ac a -
narypox vector expressing human CEA and B7.1 has been
constructed. A phase I study of 18 patients with CEA-
expressing adenocarcinoma showed it to be well-tolerated
up to 4.5 × 108 pfu with no autoimmune reactions. Two
of thirteen patients with colorectal cancer achieved stable
disease, correlating with an increase in CEA-speciﬁc pre-
cursor T cells.
Overall, immunogene therapy approaches are attrac-
tive and constitute about two thirds of the ongoing clin-
ical trials for cancer treatment. In the main, clinical tri-
als described here have so far failed to demonstrate clini-
cally signiﬁcant responses, despite clear biological activa-
tion in the form of antibody and cell-mediated response.
The discrepancy may be due, at least in part, to the dy-
namic evolution of tumour antigens as a resultof negative
selection.However,itmayalsohighlightthelimitationsof
traditional clinical trial design whereby eﬃcacy must ﬁrst
be demonstrated in the setting of advanced disease. This
may not be appropriate for immunogene therapy, which
is likely to be most eﬀective against minimal residual dis-
ease.
Mutantgenecorrection
The phenotypic correction of key genetic aberrations
in malignant cells has shown the potential to trigger the
induction of apoptosis in a range of preclinical mod-
els. Diﬀerent strategies including tumour suppressor gene
correction (eg, p53) or oncogene suppression (eg, K-ras)
have shown antitumoural eﬀects in animal models of col-
orectal cancer. p53 gene correction delivered in adenovi-
ral vectors is being tested in clinical trials in combination
with conventional chemotherapy.
About 50% of colorectal cancers harbour p53 mu-
tations. It has been shown that reexpression of wild-
type-p53 in mutated colon cancer xenografts express-
ing the mutant variant can lead to inhibition of tumour
growth and increased animal survival. A number of clin-
ical trials using a replication-deﬁcient adenoviral vector
to deliver wild-type p53 to a range of human tumours
have been carried out. Initial studies demonstrated the
safety of direct intratumoural injection of these vectors
and conﬁrmed p53 gene expression even in the pres-
ence of an antiadenovirus immune response. A phase I
study has assessed the safety and eﬃcacy of a single dose
of adenovirus-delivered p53 (SCH58500) administered
via the hepatic artery to patients with hepatic colorec-
tal metastases with the aim of maximizing tumour cell
exposure and minimizing systemic exposure. Treatment
was well-tolerated up to the maximum dose of 2.5 × 1012
virusparticleswithtoxicitycomprizingﬂu-likesymptoms
and in four out of sixteen patients, a transient asymp-
tomatic rise in liver transaminases. Of twelve patients
who went on to receive intrahepatic chemotherapy with
5-ﬂuorodeoxyuridine, eleven achieved a partial response
[12]. This compares favourably to partial response rates
of about 50% in historical controls.
Mutation of K-ras is common to many malignan-
cies of the gastrointestinal tract. This provides a poten-
tial target for antisense oligonucleotide therapy. The in-
troduction of synthetic oligonucleotides, capable of hy-
bridization to speciﬁc complementary messenger RNAs,
can block the expression of a single protein that plays a
critical role in tumour growth. Preclinical studies of K-ras
antisense therapy suggest this to be a safe, relatively non-
toxic treatment.
Virus-directedenzymeprodrugtherapy
Enzyme prodrug systems, also called suicide gene
therapy or gene-directed enzyme prodrug system
(GDEPT), are alternatives to systemic chemotherapy.
This involves gene transfer, for example, via a viral vector
(virus-directed enzyme prodrug therapy, VDEPT) to
express viral, bacterial, or fungal enzymes in tumour
cells. The enzyme can convert an inactive prodrug into a
toxic metabolite, leading to tumour cell death. Compared
to systemic chemotherapy, the merit of this approach
is of conﬁning generation of a short-lived cytotoxic
species to the tumour, reducing systemic metabolite
concentrations, and therefore limiting the potential
for toxicity to normal cells, such as bone marrow and
gastrointestinal tract. The main obstacle of this method is
the limited gene transfer eﬃciency at the tumour site by
vectors currently available. However, this hurdle may be
partially overcome by the bystander eﬀect. The bystander
eﬀect refers to the observation that only a fraction of
the total cancer cell population needs to be transfected
by the vector to lead to signiﬁcant degrees of cell kill.
This may be a local eﬀect mediated by passage of the
toxic metabolite (or other apoptotic factors from dying
cells) to neighbouring cells either by passive diﬀusion,
via gap junctions or via apoptotic vesicles. Alternatively,
there may be an immune-mediated response that could
induce a distant bystander eﬀect. This has been observed
in murine GDEPT models in which regression of distant
tumour deposits is seen in immunocompetent mice but is
less marked in athymic animals [13]. A logical extension
of this phenomenon may be to combine GDEPT with
cytokine gene therapy in order to maximize this eﬀect.
A number of bacterial/viral enzymes have been
cloned which have the capacity to catalyze the con-
version of a range of prodrugs to mechanistically di-
verse cytotoxics. Phosphorylation of ganciclovir produces
the toxic metabolite GCV-triphosphate, which competes
with dGTP and inhibits DNA synthesis. This reaction74 Daniel H. Palmer et al 2003:1 (2003)
is catalysed by herpes simplex virus (HSV)-Thymidine
Kinase (tk) 1000-fold more eﬃciently than the human
nucleoside kinase, making this an attractive model for
GDEPT. In a syngeneic murine model of colorectal can-
cer, the HSV-tk/GCV system could achieve complete tu-
mourregressionwhenonly9%ofcellsexpressthetkgene.
The lipid-insoluble GCV metabolite cannot diﬀuse into
adjacent cells suggesting that the bystander eﬀect may be
mediated by gap-junction transport or via an immune
response [14]. This system has been shown to be well-
tolerated and has achieved clinical responses in phase I
trials of brain and prostate cancer. Similar studies have
been undertaken using a replication-deﬁcient adenovirus
vector to deliver RSV-tk with similar preclinical results. A
phaseItrialutilizingdirectintratumouralinjectionofthis
vector followed by a ﬁxed dose of GCV in patients with
hepatic metastatic colorectal cancer has been undertaken.
Sixteenpatientsweretreatedwithescalatingdosesofvirus
up to 1 × 1013 particles. This treatment was well-tolerated
with no dose-limiting toxicity observed, conﬁrming the
safety of the adenovirus vector delivered by the intratu-
moural route [15].
Bacterial or fungal cytosine deaminase (CD) is able
to convert the antifungal agent, 5-ﬂuorocytosine (5-FC),
into 5-ﬂuorouracil (5-FU), one of the most eﬀective
chemotherapeutic agents for colorectal cancer. There is
some evidence suggesting that the fungal CD is superior
to its bacterial counterpart, and a profound bystander ef-
fectisseeninvivo.Signiﬁcanttumourregressionhasbeen
achievedwhenonly2%ofcellsinxenograftsexpressedcy-
tosine deaminase [16]. Furthermore, the combination of
the pyrimidine salvage pathway enzyme, uracil phospho-
ribosyl transferase (UPRT), with CD has been shown to
enhance the antitumoral eﬀect possibly by increasing the
conversion of 5-FU to 5-ﬂuoro-deoxyuracil monophos-
phate, thereby accelerating a rate-limiting step in conver-
sion of 5-FU to its cytotoxic metabolites [17]. A phase I
trial of a replication-deﬁcient adenovirus carrying the E.
coli CD gene (Ad-GVCD-10) given intratumourally fol-
lowedbyoral5-FCtopatientswithhepaticmetastaticcol-
orectalcancerisunderway.Doseescalationtoamaximum
of2×109 pfuisplanned.Thetrialcomprisestwoarms,one
of which is treated with the vector and the prodrug only,
intheother,thetumourisremovedaftertreatmentsothat
histological and molecular analysis can be undertaken.
Nitroreductase can convert the prodrug CB1954 to
a highly toxic bifunctional alkylating agent, which can
cause interstrand DNA crosslinks, leading to cell death.
This eﬀect is cell cycle independent. In cell-mixing exper-
iments, a signiﬁcant bystander eﬀect was seen when only
10% of pancreatic cancer cells expressing nitroreductase
were treated with CB1954 [18]. A phase I dose-escalating
studyoftheprodrug,CB1954hasalreadybeencompleted,
establishing the dose of CB1954 that can be delivered
safely by the intravenous (IV) and intraperitoneal (IP)
routes. Pharmacokinetic analysis showed that venous lev-
els suﬃcient for clinically signiﬁcant prodrug activation
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Figure 1. The use of replication-competent viral vector as a car-
rier for therapeutic gene delivery. The potential advantages are:
(1) the dual killing eﬀect caused by viral oncolysis and the ther-
apeutic gene system, for example, enzyme prodrug system; (2)
the continuing infection by the replicated viruses to surround-
ing tumor cells which were not infected initially.
could be achieved, based on data from preclinical models
with IP concentrations of around 100µmol [19]. Mean-
while, in the other arm of this ongoing phase I study, an
E1-andE3-deletedadenoviruscontainingthenitroreduc-
tase gene, under the control of a cytomegalovirus pro-
moter,isgiventopatientswithhepaticcolorectalmetasta-
sis or hepatocellular carcinoma by ultrasound-guided in-
tratumoral injection. CB1954 will be given intravenously
48hours after viral injection, once an adequate level of ni-
troreductasegeneexpressionhasbeendetectedinresected
hepatic tumours from operable patients. So far, prelimi-
nary data from this trial have demonstrated the safety of
intratumoural vector administration up to 5 × 1011 virus
particles. Immunohistochemical analysis of resected tu-
mours has conﬁrmed nitroreductase expression which in-
creases in a dose-dependent manner. Generally, the viral
vectors used in these trials were delivered by intratumoral
injection directly to the tumour site. This approach se-
cures accurate tumour targeting but may limit the use to
solitary tumours rather than to systemic disease. Clinical
eﬃcacy has not yet been shown.
A further level of speciﬁcity for these systems is the
insertion of a tumour speciﬁc promotor, for example,
the CEA tumour promoter, to regulate gene expression
so that even if normal cells were infected, the enzyme
would not be transcribed. It is envisaged that this would
allow regional administration of the vector to the liver
in patients undergoing resection of a primary colorec-
tal tumour. This would be followed by systemic admin-
istration of prodrug. Given the favourable growth kinet-
ics of microscopic metastases following resection of the
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adjuvant setting. A further extension of the targeted ap-
proach would be to consider intrahepatic arterial (IHA)
administration of the vector. The liver is a common site
of metastasis for many cancer types and, once established,
draw their blood supply from the hepatic artery. It is pos-
sible to cannulate the artery and implant a catheter which
allows repeated administration of virus and/or drug, gen-
erating high local concentrations of the relevant thera-
peutic agent and perhaps increasing the opportunity for
transfection and prodrug activation. In the adjuvant set-
ting, where micrometastases are more likely to be served
bytheportalvein,itispossibletodelivertheVDEPTcom-
ponents by an intraportal catheter inserted at the time of
resection of the primary colorectal cancer.
Oncolyticvirustherapy
In recent years, genetically modiﬁed oncolytic viruses
including adenovirus, herpes simplex virus, and reovirus
have been developed and tested. These viruses require key
tumourigenicpathwaystobemutatedforviralreplication
andhencecanselectivelyreplicateinandlysetumourcells
while sparing normal cells [20]. Among them, mutants of
adenovirusandherpessimplexvirusesarealreadyintrials
for various cancers.
The development of replication-competent viral vec-
tors may have the potential to improve the relatively low
levels of transgene expression in many gene therapy pro-
tocols.Itisenvisagedthatconditionallyreplicatingvectors
may be able to overcome these hurdles and, further, may
have the potential to reach disseminated metastases.
Oncolyticadenovirus
The wild-type adenovirus was ﬁrst used in the treat-
ment of cervical cancer. Recently, an E1B-attenuated ade-
novirus, dl1520 (ONYX-015) has been tested on more
than 200 patients with head and neck cancer, hepatic col-
orectal metastases, ovarian cancer, and pancreatic cancer.
This mutant virus was engineered not to express the E1B-
55-kDa virus protein and, therefore, was initially reported
to replicate speciﬁcally in cancer cells lacking functional
p53, leading to cell lysis. However, it was subsequently
found that this virus could also replicate eﬃciently in sev-
eral tumour cell lines with wild-type p53. These contra-
dictory results raised the doubt about the speciﬁcity of
dl1520-mediated killing eﬀect in p53-mutated cells. Nev-
ertheless, recent data has shown that the loss of p14-
mediated Mdm2 inhibition plays an important role in
supporting the replication of this virus in tumour cells
with wild-type p53.
In a phase I/II trial, ONYX-015 was administered via
hepatic artery infusion for patients with metastatic hep-
atic tumours. Two courses of a ﬁve-day infusion of 5-
FU/folinic acid were given concurrently. The virus was
well-tolerated at the dose of 1011 pfu/infusion without
dose-limiting toxicities, although most of the patients de-
veloped grade-I/II fever and a few patients developed rig-
ors after viral injection. Preliminary data showed partial
responses in two of the four evaluable patients, which is
comparable to the standard chemotherapeutic treatment
[21].
Another trial using the same virus administered via
hepatic artery infusion, intravenous infusion, or intratu-
moralinjection,withoutchemotherapy,wasconductedin
16 patients with primary or metastatic hepatic tumour
(mainly from colorectal primaries). Tumour necrosis af-
ter viral injection was seen on CT scanning and histologi-
cal analysis in all patients. No severe side eﬀects were ob-
served at a dose of 3 × 1011 pfu [22].
In summary, ONYX-015 has been investigated in sev-
eral clinical trials, treating a range of tumours. Doses up
to 2 × 1012 virus particles have been well-tolerated when
administered intratumourally, via the hepatic artery, in-
traperitoneally, and intravenously. No dose-limiting tox-
icity has been observed. Virus replication has been ob-
served after administration by all routes, but to a vari-
able extent depending on tumour type. There is also a
conﬁrmation that distant tumours can be infected fol-
lowing systemic delivery. Interestingly, ONYX-015 has
demonstrated very little eﬃcacy as a single agent in
head and neck cancer (0–14% objective response rate).
However, clinical beneﬁt has been seen where combined
with chemotherapeutic agents. ONYX-015, in combina-
tion with chemotherapy (5-FU and cisplatin), has also
shown promising results in a trial of head and neck tu-
m o u r s ,w i t hac o m p l e t er e s p o n s er a t eo f2 7 %a n dap a r -
tial response rate of 36% [23]. The combination of on-
colytic virus with chemotherapeutic agents seemed syner-
gistic but randomised, properly, powered trials compar-
ing chemotherapy versus chemotherapy plus virus are re-
quired.
The original concept that genetically engineered
viruses could speciﬁcally target tumour cells derived from
theobservationthatdeletionoftkgenefromHSVallowed
viral replication exclusively in mitotic cells. The current
oncolytic HSV’s are engineered with mutations in one or
both of two other genes; viral ribonucleotide reductase
(ICP6), the loss of which restricts lytic virus replication
to the dividing cells that retain suﬃcient ribonucleotide
reductase activity to support the replication of the virus;
and viral ICP34.4, mutation of which allows continued
protein synthesis by blocking the shutdown of host cell
protein synthesis normally associated with HSV infection
thereby enhancing the generation of virus progeny. Such
attenuated HSV’s have been engineered and exploited in
cancer trials for brain tumours and prostate cancer [24].
Replicating viruses have the potential to infect a
greater proportion of tumour cells and to increase trans-
gene expression. It is attractive, therefore, to combine
these viruses with gene therapy strategies such as pro-
drug activation or cytokine expression by inserting the
appropriate cDNA into the vector (Figure 1). Preclinical
studies using the combination of a replication-competent
HSV vector encoding the tk gene have been performed. In
a colorectal cancer model, the addition of GCV actually76 Daniel H. Palmer et al 2003:1 (2003)
reduced the cytotoxic eﬀect of the oncolytic vector, prob-
ably because of the antiviral activity of the activated pro-
drug. More encouraging results have been reported with
E1B-attenuated adenovirus vectors encoding a combina-
tion of CD and tk. Data showed that the vector alone was
cytotoxic, but the addition of both 5-FU and GCV further
enhancedcellkilling[25].Interestingdataregardingapo-
tentially synergistic interaction between oncolytic viruses
and radiotherapy is also emerging, with evidence that ra-
diotherapy may enhance viral replication within tumours
[25].
Overall, progress is being made in the clinical devel-
opment of oncolytic viruses. Future clinical studies will
address the optimum combination of replicating vector,
gene insert, chemotherapy, and radiotherapy to maximize
their therapeutic potential.
FUTURE DEVELOPMENTS
Gene therapy is now no longer in its basic scientiﬁc or
clinical infancy. It is a toddler, and the initial expressions
and gasps of delight that surrounded its conceptual birth
have somewhat given way to the recognition that there
will now be a longer haul through school days to adoles-
cence before we can see, through properly powered ran-
domized clinical trials, its true worth. In the meantime,
several challenges remain.
(i) Improving the eﬃciency of gene transfer:
The recent development of replication-competent
vectors for cancer gene therapy may improve gene
transfer eﬃciency.
(ii) Improving the potency of antitumor eﬀect:
Approaches to improve the potency of antitumor
eﬃcacy include, combination of gene therapy with
conventional chemotherapy, inclusion of diﬀerent
enzyme activating genes within a single vector, and
utilization of cytotoxic and immune eﬀector sys-
tems.
(iii) Speciﬁc gene expression at tumour sites to avoid
toxicity to normal tissues:
To limit speciﬁc gene expression to the site of tu-
mours, tumour- or tissue-speciﬁc promoters such
as CEA, Prostate Speciﬁc Antigen, and Alpha-
fetoprotein can be used or retargeted viruses incor-
porating novel ligands in cell binding domains.
(iv) Safety of viral vectors:
Safety is still a concern, especially when viral vec-
tors are used. For herpes simplex virus, the infec-
tion of this virus can be eradicated by antiviral
drug (acyclovir or ganciclovir). However, for aden-
ovirus, viral clearance is dependent on the immune
system. Therefore, screening should rule out the
immunocompromised patients from adenovirus-
mediated gene transfer protocols. Safety can be po-
tentially improved by the development of gutless
virus, chimaeric virus, minivirus, or complemen-
tary oncolytic virus.
(v) Noninvasive monitoring of transgene expression:
It is critical that noninvasive imaging systems are
developed, that can detect transgene expression in
vivo and evaluate the pharmacokinetics of genetic
medicinestoallowthoroughpharmacologicalstud-
ies.
It is likely that gene therapies will be integrated with
existing treatment modalities. The envisaged future prac-
tice for cancer treatment may involve a multimodality ap-
proach, integrating curative or debulking resection, fol-
lowed by adjuvant therapies including concurrent or se-
quential gene therapy, chemotherapy, and radiotherapy.
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